培美曲塞、吉西他滨联合顺铂治疗初治晚期非小细胞肺癌临床疗效及安全分析

Analysis of Clinical Efficacy and Safety of Pemetrexed,Gemcitabine Combined With Cisplatin in the Treatment of Advanced Non-small Cell Lung Cancer

目的探讨培美曲塞、吉西他滨分别联合顺铂治疗初治晚期非小细胞肺癌临床疗效及安全。方法选择2012年1月—2014年1月在我院化疗治疗的非小细胞肺癌患者76例的临床资料进行回顾性分析,其中40例患者采用培美曲塞联合顺铂治疗为A组,36例患者采用吉西他滨联合顺铂治疗为B组。比较两组患者的临床疗效、不良反应情况以及生存率。结果 A组非鳞癌亚组以及腺癌亚组的PR率均高于B组,差异有统计学意义(P<0.05)。两组患者血小板下降、白细胞下降、血红蛋白下降以及脱发等发生率比较,差异有统计学意义(P<0.05)。结论培美曲塞联合顺铂治疗初治晚期非鳞癌以及腺癌非小细胞肺癌缓解率高于吉西他滨联合顺铂,不良反应较轻。

Objective To discuss the clinical efficacy and safety analysis of pemetrexed, gemcitabine combined with cisplatin in the treatment of advanced non-small cell lung cancer. Methods Clinical data of 76 cases with non-small cell lung cancer from January 2012 to January 2014 were retrospectively analyzed. 40 cases of patients in group A was treated with pemetrexed combined with cisplatin, and 36 cases of patients in group B was treated with gemcitabinecombined with eisplatin. Clinical efficacy, adverse reactions and survival rate of two groups were compared. Results PR rate of non-squamous cell subgroup and adenocarcinoma subgroup of group A was higher than group B, which showed significant difference （P〈0.05）. Two groups of platelets, white blood cells and hemoglobin decreased, hair loss were compared with each other, the differences were statistically significant （P〈0.05）. Canelusion PR rate of combination of pemetrexed and cisplatin in the treatment of advanced non-small cell lung cancer and non-small cell lung cancer is higher than that of gemcitabine combined with cisplatin, and the adverse reactions arelighter.